PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients

By sjmartinez • October 23, 2022

Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BAM, Becher H, Blomqvist C, Bojesen SE, Bolla MK, Camp NJ, Czene K, Devilee P, Eccles DM, Fasching PA, Figueroa JD, Flyger H, García-Closas M, Haiman CA, Hamann U, Hopper JL, Jakubowska A, Leeuwen FE, Lindblom A, Lubiński J, Margolin S, Martinez ME, Nevanlinna H, Nevelsteen I, Pelders S, Pharoah PDP, Siesling S, Southey MC, van der Hout AH, van Hest LP, Chang-Claude J, Hall P, Easton DF, Steyerberg EW, Schmidt MK. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients. Breast Cancer Res. 2022 Oct 21;24(1):69. doi: 10.1186/s13058-022-01567-3. PMID: 36271417.

Tags: BCAC, BRCA1/2 germline mutation, Breast Cancer Association Consortium, Breast cancer genetic predisposition, Clinical decision-making, Contralateral breast cancer, Contralateral preventive mastectomy, Hematology/Oncology, polygenic risk score, Prediction performance, Publications, Risk prediction

Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial

Kater AP, Janssens A, Eradat H, Offner F, Sandoval-Sus JD, Shadman M, Poulsen CB, Christensen JH, Thompson MC, Guan M, Steele AJ, Rios M, Holst[...]

Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

Brady MR, Matulionis N, Christofk HR, Garon EB, Lisberg A, Shackelford DB, Momcilovic M. Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous[...]

CD146+ pericyte-like lung cancer brain metastatic stem cells promote tumor angiogenesis through dual regulatory effects on the VEGF/VEGFR axis

Liu W, Duan W, Xia S, Liu Y, Chu H, Liang K, Fang S, Lin M, Wei S, You X, Hu Q, Qi J, Wang[...]